LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

Search

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

510.25 -0.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

505.05

Max

521.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-36M

-94M

Verkoop

-9.7M

311M

EPS

-1.38

Winstmarge

-30.318

Werknemers

915

EBITDA

-36M

-86M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.37% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

66M

12B

Vorige openingsprijs

510.88

Vorige sluitingsprijs

510.25

Nieuwssentiment

By Acuity

50%

50%

143 / 342 Rangschikking in Healthcare

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat